Setmelanotide | CAS 920014-72-8 | MC4R Agonist (Research Use Only) | Knowlux

Product Description

Setmelanotide, CAS 920014-72-8, is a synthetic cyclic peptide supplied by Knowlux for laboratory research use. It is also known as RM-493 or BIM-22493. The molecule is an 8-amino-acid cyclic peptide with a disulfide bridge between Cys2 and Cys8, and its sequence is Ac-Arg-Cys-D-Ala-His-D-Phe-Arg-Trp-Cys-NH2. The molecular formula is C49H68N18O9S2 and the molecular weight is 1117.31 g/mol (free peptide basis). Each lot is released with a lot-specific COA, MSDS and full analytical traceability.

Salt form and CAS clarification: CAS 920014-72-8 is consistently recorded across KEGG, PubChem and DrugBank as setmelanotide (free peptide). Commercial listings sometimes reference CAS 1294000-61-5, which ChemicalBook records as a distinct chemical entity with a different molecular formula (C14H14ClF5N4O2S); that CAS does not correspond to setmelanotide and should not be used for this product. A trifluoroacetate salt form is also available (PubChem CID 138911306, molecular weight 1231.3 g/mol). Knowlux supplies the free peptide form and declares the counter-ion on each COA. Setmelanotide is approved by the FDA (Imcivree, 2020) for specific genetic causes of obesity, including POMC, PCSK1, and LEPR deficiencies and Bardet-Biedl syndrome; that approval is specific to the finished pharmaceutical product and does not extend to this research-grade supply.

Product Parameters

Item	Specification
Product Name	Setmelanotide
Synonyms	RM-493; BIM-22493
CAS No.	920014-72-8 (free peptide)
Related CAS	Setmelanotide TFA: PubChem CID 138911306
Molecular Formula	C49H68N18O9S2
Molecular Weight	1117.31 g/mol (free peptide)
Sequence	Ac-Arg-Cys-D-Ala-His-D-Phe-Arg-Trp-Cys-NH2 (disulfide bridge Cys2-Cys8)
Sequence Length	8 amino acids, cyclic
Key Structural Features	N-terminal acetylation; C-terminal amide; D-Ala and D-Phe residues; disulfide cyclisation
Appearance	White to off-white lyophilized powder
Solubility	Soluble in water and aqueous buffers
Purity	>=98.0% (HPLC); >=99.0% available on request
Identity	Confirmed by LC-MS and peptide mapping
Grade	Research grade
Counter-ion	Acetate or TFA (lot-specific, declared on COA)
Moisture	<=8.0% (Karl Fischer)
Storage	-20 C, protected from light and moisture; reconstituted solution 2-8 C, use within 7 days
HS Code	2937.19.00
Packaging	1 mg / 5 mg / 10 mg / 50 mg / 100 mg vial; bulk on request
MOQ	10 mg (research grade); 100 mg (bulk)
Supply Ability	Milligram to gram scale
Application	Laboratory research use only
Origin	China

Product Details

1. Overview

Setmelanotide is a synthetic cyclic peptide that acts as a selective agonist of the melanocortin-4 receptor (MC4R), a G protein-coupled receptor in the hypothalamus that regulates energy balance and appetite. It was developed by Rhythm Pharmaceuticals and received FDA approval in November 2020 under the brand name Imcivree, making it the first available treatment for obesity caused by specific genetic defects in the MC4R pathway, including pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), and leptin receptor (LEPR) deficiencies, as well as Bardet-Biedl syndrome. Knowlux supplies setmelanotide as a research-grade peptide for laboratory and analytical use; this supply is not intended for human administration and does not constitute a finished drug product.

2. Mechanism of Action (Research Context)

Published pharmacological data describe setmelanotide as a selective MC4R agonist with an EC50 of 0.27 nM and a Ki of 2.1 nM at the human receptor. Activation of MC4R in the hypothalamus is proposed to reduce hunger and increase energy expenditure, counteracting the hyperphagia and reduced satiety that characterize MC4R-pathway genetic obesity disorders. The peptide incorporates D-amino acids (D-Ala, D-Phe) and a disulfide bridge that confer metabolic stability relative to native melanocyte-stimulating hormones. These descriptions are derived from published research and pharmacological data and are provided for scientific reference only. Knowlux makes no claims regarding the efficacy, safety, or suitability of this product for any human application. Promotion of setmelanotide for weight loss, appetite suppression, or any clinical indication is not supported by Knowlux and is inconsistent with research-use-only supply.

3. Quality Control

Test Item	Method
Purity	RP-HPLC
Identity & molecular mass	LC-MS (deconvoluted)
Sequence confirmation	Peptide mapping / amino acid analysis
Disulfide bridge integrity	LC-MS under non-reducing conditions
Counter-ion content	Ion chromatography (acetate or TFA)
Moisture	Karl Fischer
Appearance	Visual
Related substances	RP-HPLC
Microbial limits	Membrane filtration (on request)

Full COA, MSDS, and lot-specific chromatograms are issued with each shipment. Custom specifications and third-party inspection can be arranged.

4. Applications

• Reference standard for MC4R agonist analytical method development

• MC4R binding and functional assay development

• Melanocortin signalling and energy homeostasis research models

• Formulation development for long-acting injectable peptides

• LC-MS and immunoassay calibrators

5. Packaging, Storage & Shipping

Lyophilized powder: amber glass vial under nitrogen headspace, sealed with butyl stopper and aluminium crimp. Secondary packing: tamper-evident, light-protected carton with desiccant. Cold-chain shipping with validated gel packs and temperature logger; dry ice for -20 C shipments. COA, MSDS, packing list and certificate of origin issued with each shipment.

6. Documentation Support

Per lot: COA, MSDS, certificate of origin, residual solvent statement, counter-ion specification. Regulatory packages (specification summaries, audit support) available on a project basis.

About Knowlux

Knowlux Biotechnology is a GMP-oriented manufacturer and supplier of peptides, APIs and fine-chemical research compounds, operating from Hubei, China. We serve research groups, CDMOs and distributors in more than 40 countries, and support contract synthesis, custom packaging and technical documentation requests.

Compliance Statement

This product is supplied for laboratory research use only. It is not for human or animal administration, not for diagnostic or therapeutic use, not for retail sale, and not for personal use. Setmelanotide is approved as a prescription medicine (Imcivree) by the FDA (2020) and other regulatory agencies for specific genetic causes of obesity; that regulatory status is specific to the approved pharmaceutical product and does not extend to this research-grade supply as sold by Knowlux. Research context statements are for scientific reference only and do not constitute medical advice, promotional claims, or dosing guidance.